Biomaterials & Tissue Engineering Patents: Leaders & White Space 2026
- Concentrated at the top. The five leading assignees together hold 26.5% of all 6,380 records in scope, with the top ten reaching 35.7% — a dense core surrounded by a long tail.
- Filing has cooled from its 2021 pace. Documented filings fell from 202 in 2021 to 123 in 2024, a 39% drop over that three-year span — the most recent complete years the data supports.
- Sterilising and disinfecting claims dominate the mix. A61L covers 51.3% of all 6,380 records, well ahead of medicinal preparations (A61K, 36.7%) and implants and prostheses (A61F, 31.4%).
Filing growth compares 2021 (202 records) with 2024 (123) — a three-year span. 2024 is the most recent year we treat as complete: publication lags filing by roughly 18 months, so 2025 onwards are still filling in and any growth rate that ends there would understate the field. Top-5 share is the combined record count of the five largest assignees divided by all 6,380 records in scope (CR5), not by the ranked leaders only.
What the filing record shows
Biomaterials and tissue engineering patenting sits at the intersection of implant design, surface chemistry and regenerative biology. The dataset behind this page spans 6,380 published records filed against a search built around implant fixation, device geometry and physiological interface claims — the practical, manufacturable end of the field rather than pure biology research. Publication lags filing by roughly 18 months, so the last one to two years in any trend chart understate real filing activity.
The picture that emerges is a dense, well-occupied core surrounded by a long tail of single- or few-filing entrants. Sterilisation and disinfection claims (A61L) touch over half of all records, reflecting how much of this field is really about making implant materials safe for the body rather than about novel geometries alone. Filing peaked in 2017 and has since eased off its high, though the most recent years are still filling in.
Let an AI agent run this analysis on your own technology
Pick a task. Every answer cites the patents behind it.
Filing trend and technology composition
Two views of the same 6,380-record corpus: how filing activity has moved year over year, and how records distribute across IPC subclasses.
Filing activity, 2015–2026
Filings peaked in 2017 at 329 records. From a more recent high of 202 in 2021, filings fell to 123 in 2024 — a 39% decline over that span. 2025 and 2026 figures are still incomplete due to publication lag and should not be read as a continued decline.
Technology composition by IPC subclass
A61L (sterilising and disinfecting) leads at 51.3% of all 6,380 records, followed by A61K (medicinal preparations) at 36.7% and A61F (implants and prostheses) at 31.4%. Because records can carry multiple IPC classes, these shares sum to well over 100% — each is calculated against the full 6,380-record base, not against each other.
Shares are the percentage of the 6,380 records in scope. A patent can carry several IPC classes, so the shares add up to more than 100%.
Go deeper on Biomaterials & Tissue Engineering Patent Landscape with Eureka
This page is one run against one query. Ask Eureka your own question about biomaterials & tissue engineering patent landscape and every answer comes back with the patent numbers behind it.
Try EurekaThe most-cited prior art in this space
Hybrid Material Implant Having Variable Porosity (US20170348462A1)
The filing describes an implant material for filling bone defects, bone regeneration and bone tissue engineering: a hybrid of a biodegradable polymer soluble in one solvent and insoluble in a second, layered with a bioactive glass (SiO2 and CaO, optionally with P2O5 or strontium doping). The implant is built with a layered porosity structure, including a porous region with more than 90% of its pores above a specified largest dimension.Filed by Centre National de la Recherche Scientifique, published 2017-12-07.
| # | Publication no. | Patent title | Citations |
|---|---|---|---|
| 1 | US6599323B2 | Reinforced tissue implants and methods of manufacture and use | 1,725 |
| 2 | US6863694B1 | Osteogenic implants derived from bone | 1,622 |
| 3 | US20020127265A1 | Use of reinforced foam implants with enhanced integrity for soft tissue repair and regeneration | 1,504 |
| 4 | US7009039B2 | Plasma protein matrices and methods for their preparation | 1,412 |
| 5 | US6852330B2 | Reinforced foam implants with enhanced integrity for soft tissue repair and regeneration | 1,387 |
| 6 | US6884428B2 | Use of reinforced foam implants with enhanced integrity for soft tissue repair and regeneration | 1,344 |
| 7 | US6147135A | Fabrication of biocompatible polymeric composites | 1,232 |
| 8 | US7964206B2 | Porous medical device and method for its manufacture | 1,138 |
| 9 | US8389588B2 | Bi-phasic compressed porous reinforcement materials suitable for implant | 1,128 |
| 10 | US20100137990A1 | Porous Substrates for Implantation | 1,118 |
Citation counts inside a searched corpus favour older filings by construction — read them as a signal of influence on later filers, not as a measure of current commercial relevance.
Each row carries its publication number; clicking a row searches Eureka by that number.
Put your own technology through the same analysis
Eureka on the web
When you want the answer in the next five minutes.
The agent works the prompt against patents and technical literature, citing every source.
Run your analysis now →MCP server & REST API
When it has to run inside your own pipeline.
Patent search, landscape analysis and assignee resolution as MCP tools. Drop them into any agent framework, or call REST directly.
Browse MCP servers →Reading the concentration and the mix
Three findings that shape how a new entrant should think about freedom to operate in this field.
The core is occupied, but not by many hands
The five leading assignees hold 26.5% of all 6,380 records between them, rising to 35.7% for the top ten. That leaves nearly two-thirds of the corpus spread across a long tail of smaller filers, which is where most freedom-to-operate work in this field actually happens.
Sterilisation claims outnumber implant geometry claims
More records carry an A61L sterilising and disinfecting class than any other subclass, ahead of medicinal preparations (A61K, 36.7%) and implants and prostheses (A61F, 31.4%). A biomaterial that cannot show a defensible sterilisation or surface-treatment claim is entering the most crowded part of the map.
Activity has eased from its recent high
Documented filings dropped from 202 in 2021 to 123 in 2024. That is the most recent span the data can support as complete; 2025 and 2026 are still being published and should not yet be read as a continuing decline.
A tight cluster of co-filers sits at the top of the ranking
Several of the leading individual assignees file jointly and repeatedly with one another, with the strongest pair sharing 282 records. This kind of clustered co-filing usually signals a single working group operating across related legal entities rather than independent convergence on the same claims.
Eureka can read the same corpus for gaps instead of for coverage: under-claimed branches adjacent to biomaterials & tissue engineering patent landscape, with the prior art for and against each one.
Who is filing, and where the room to move still is
The ranking covers the 100 companies the data endpoint returns for this search — not a top-50 or top-100 industry list, but the full set the assignee ranking surfaces for this query.
One filer sits well ahead of the field
The leading assignee's 663 records dwarf the fifth-place figure of 256, meaning the top of this ranking is not evenly spread — a single filer accounts for a disproportionate share of the top-five total before the numbers flatten out.
The drop-off by rank ten is steep
Tenth place holds 82 records against the leader's 663 — an eightfold gap. Past the top few names, filing volume per assignee falls quickly, which is consistent with a long tail of smaller or single-purpose filers rather than a second tier of large competitors.
US and PCT routes carry the bulk of filings
The United States (1,903) and WIPO/PCT (1,086) are the two largest receiving offices, ahead of Europe (1,010), Australia (438), Canada (389) and Austria (247). Filing strategy in this field is built around US priority and PCT internationalisation more than direct regional filing.
| Assignee | Recent year | YoY |
|---|---|---|
| MONDOBIOTECH LABES | 0 | — |
| BEVEC DORIAN | 0 | — |
| CAVALLI FABIO | 0 | — |
| BACHER GERALD | 0 | — |
| CAVALLI VERA | 0 | — |
| Warsaw Orthopedic, Inc. | 0 | — |
| DePuy Synthes Products, Inc. | 0 | — |
| Trustees of Tufts College | 0 | — |
Using this landscape to plan a filing or FTO position
The data points to where claim space is dense and where it thins out — the next step is testing a specific concept against it.
Check a concept against the cited core
The most-cited records in this corpus, several tied to reinforced tissue and foam implant claims, define the prior art that any new implant material or fixation concept will be measured against.
Explore prior art in Eureka →Map a specific sub-area before drafting claims
Under-claimed branches like layered porosity gradients or peptide-functionalised surfaces sit outside the densest IPC classes — worth a targeted search before committing claim language.
Run a white space search in Eureka →Watch the leading co-filing cluster
A small group of assignees files jointly and repeatedly at the top of this ranking; tracking their combined output is more informative than watching any one entity alone.
Track assignee activity in Eureka →Common questions on biomaterials and tissue engineering patents
It is moderately concentrated at the very top and then spreads out quickly. The five leading assignees hold 26.5% of all 6,380 records in scope, and the top ten hold 35.7%. Past that point, volume per assignee drops sharply — tenth place holds 82 records against the leader's 663 — so the majority of the field is a long tail of smaller filers rather than a handful of dominant players controlling everything.
A61L covers 51.3% of all 6,380 records, more than any other IPC subclass in this dataset, because implant biomaterials cannot be approved or commercialised without a defensible sterilisation or surface-treatment approach. This is not a niche add-on to implant design — it is treated as core intellectual property alongside the implant geometry or material itself, which is why it outpaces even medicinal preparations (A61K, 36.7%) and implants and prostheses (A61F, 31.4%).
Filings fell from 202 in 2021 to 123 in 2024, a 39% drop over that three-year span, which is the most recent period the data can treat as complete. Figures for 2025 and 2026 are still incomplete because publication typically lags filing by around 18 months, so it would be premature to call this a continuing decline rather than a normal reporting gap. The peak year in the full trend was 2017, at 329 records.
This filing, from Centre National de la Recherche Scientifique, claims a hybrid implant material combining a biodegradable polymer with a bioactive glass (SiO2 and CaO, optionally doped with strontium), arranged in a layered porosity structure with a porous region where more than 90% of pores exceed a specified size. Anyone working on layered or graded-porosity bone scaffolds using a similar polymer-glass hybrid should review its claim scope closely, since it sits directly in that design space. It does not block every bone-regeneration approach — polymer-only or ceramic-only scaffolds without the layered hybrid structure sit outside its specific claim language.
The densest claim activity sits in sterilisation methods, medicinal preparation formulations and core implant/prosthesis geometry — those areas carry the highest IPC shares in this dataset. Sub-areas like layered porosity gradients, peptide-functionalised implant surfaces and specific bioactive glass doping variants show up far less often and sit outside the top assignee cluster, making them worth a closer, targeted prior-art search before drafting new claims. This is inferred from where filing density is low relative to the rest of the corpus, not a guarantee that a given claim is unfiled elsewhere.
Research Biomaterials & Tissue Engineering Patent Landscape in depth with Eureka
Go past this page: query the whole biomaterials & tissue engineering patent landscape corpus yourself, in your own scope.
Every answer comes back with patent numbers you can open.
Disclaimer. This page is generated from Patsnap Eureka data drawn from a limited snapshot of global patent and scientific-literature records, and is provided for general information and reference only.
Patent data carries inherent limitations: recent filings (typically the most recent 18–24 months) are under-counted due to standard publication lag; counts may be reported at either a patent-family or a patent-record basis and are not always directly comparable; classification, applicant-name, and citation data may contain errors, duplicates, or omissions; and the underlying search query defines and constrains the scope shown. As a result, the analysis may be incomplete or inaccurate and may not reflect the full technology landscape.
Nothing on this page constitutes an exhaustive prior-art, novelty, freedom-to-operate, or validity search, nor does it constitute legal, financial, investment, or professional advice, and it should not be relied upon as such. Any patent, commercial, or strategic decision should be verified independently and reviewed with qualified patent, legal, and domain professionals. Patsnap makes no warranties, express or implied, as to the accuracy, completeness, or fitness for any particular purpose of the information presented.
Machine translation. Assignee and organisation names originally recorded in Chinese, Japanese or Korean have been rendered into English by an AI translation step so that the tables stay readable. These renderings are best-effort and may not match a company’s registered English name; the original name is what the underlying patent record carries, and it is what any Eureka query launched from this page uses.